Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Payables (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Payables for 3 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 20.36% to $15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.2 million, a 20.36% increase, with the full-year FY2025 number at $15.2 million, up 20.36% from a year prior.
  • Payables was $15.2 million for Q4 2025 at Nuvation Bio, down from $21.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $28.0 million in Q2 2025 to a low of $2.2 million in Q4 2023.
  • A 3-year average of $11.9 million and a median of $13.9 million in 2024 define the central range for Payables.
  • Biggest YoY gain for Payables was 776.78% in 2024; the steepest drop was 17.28% in 2024.
  • Nuvation Bio's Payables stood at $2.2 million in 2023, then skyrocketed by 471.8% to $12.6 million in 2024, then increased by 20.36% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Payables are $15.2 million (Q4 2025), $21.0 million (Q3 2025), and $28.0 million (Q2 2025).